The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy

Ruggero De Maria Marchiano, Teresa Gamucci, Daniele Sergi, Patrizia Vici, Marcella Mottolese, Laura Pizzuti, Maddalena Barba, Francesca Sperati, Irene Terrenato, Anna Di Benedetto, Clara Natoli, Domenico Angelucci, Maria Teresa Ramieri, Luigi Di Lauro, Domenico Sergi, Monica Bartucci, Rosanna Dattilo, Alfredo Pagliuca, Marcello Maugeri-Saccà

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

28 Citazioni (Scopus)

Abstract

Activation of the Hippo transducer TAZ is emerging as a novel oncogenic route in breast cancer and it has been associated with breast cancer stem cells. Additionally, TAZ expression has been linked with HER-2 positivity. We investigated the association between TAZ expression and pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.TAZ was assessed in diagnostic core biopsies by immunohistochemistry. To categorize samples with low TAZ and samples with high TAZ we generated a score by combining staining intensity and cellular localization. The pathological complete response rate was 78.6% in patients with low TAZ tumors and 57.6% in patients with high TAZ tumors (p=0.082). In HER2-enriched tumors there was no signi cant association between TAZ and pathological complete response, whereas in the luminal B subtype the pathological complete response rate was 82.4% in tumors with low TAZ and 44.4% in tumors with high TAZ (p=0.035). This association remained statistically signi cant when restricting our analysis to triple-positive tumors with expression of both estrogen receptor and progesterone receptor ≥ 50% (p=0.035). Results from this exploratory study suggest that the TAZ score ef ciently predicts pathological complete response in Luminal B, HER2-positive breast cancer patients who received neoadjuvant chemotherapy and trastuzumab.
Lingua originaleEnglish
pagine (da-a)9619-9625
Numero di pagine7
RivistaOncotarget
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • breast cancer

Fingerprint Entra nei temi di ricerca di 'The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy'. Insieme formano una fingerprint unica.

Cita questo